SG Americas Securities LLC Buys 117,962 Shares of Organon & Co. $OGN

SG Americas Securities LLC lifted its position in Organon & Co. (NYSE:OGN) by 74.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 276,086 shares of the company’s stock after buying an additional 117,962 shares during the period. SG Americas Securities LLC owned about 0.11% of Organon & Co. worth $1,980,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in OGN. Vanguard Group Inc. boosted its stake in Organon & Co. by 11.3% during the 3rd quarter. Vanguard Group Inc. now owns 35,928,403 shares of the company’s stock valued at $383,715,000 after purchasing an additional 3,650,860 shares during the last quarter. Norges Bank bought a new stake in Organon & Co. in the 2nd quarter worth approximately $19,778,000. AQR Capital Management LLC grew its position in Organon & Co. by 136.1% in the 2nd quarter. AQR Capital Management LLC now owns 3,254,884 shares of the company’s stock worth $31,507,000 after purchasing an additional 1,876,264 shares during the period. Balyasny Asset Management L.P. raised its stake in Organon & Co. by 102.1% during the 3rd quarter. Balyasny Asset Management L.P. now owns 2,240,149 shares of the company’s stock valued at $23,925,000 after buying an additional 1,131,941 shares during the last quarter. Finally, Gotham Asset Management LLC lifted its holdings in shares of Organon & Co. by 37.2% during the 3rd quarter. Gotham Asset Management LLC now owns 3,713,204 shares of the company’s stock valued at $39,657,000 after buying an additional 1,007,691 shares during the period. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Wall Street Analyst Weigh In

OGN has been the topic of several analyst reports. Zacks Research downgraded shares of Organon & Co. from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. Barclays upped their target price on shares of Organon & Co. from $7.50 to $8.00 and gave the stock an “underweight” rating in a report on Tuesday, February 24th. Finally, Wall Street Zen lowered Organon & Co. from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and five have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average price target of $8.50.

Organon & Co. Stock Performance

NYSE OGN opened at $6.35 on Monday. The business has a 50 day simple moving average of $7.14 and a two-hundred day simple moving average of $7.86. Organon & Co. has a 1-year low of $5.69 and a 1-year high of $14.70. The stock has a market capitalization of $1.65 billion, a PE ratio of 8.95, a P/E/G ratio of 0.59 and a beta of 0.67. The company has a debt-to-equity ratio of 11.47, a current ratio of 1.82 and a quick ratio of 1.23.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Thursday, February 12th. The company reported $0.63 EPS for the quarter, missing the consensus estimate of $0.73 by ($0.10). The business had revenue of $1.51 billion for the quarter, compared to the consensus estimate of $1.52 billion. Organon & Co. had a net margin of 3.01% and a return on equity of 122.01%. Organon & Co.’s revenue for the quarter was down 5.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.90 EPS. On average, research analysts predict that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 12th. Stockholders of record on Monday, February 23rd were issued a $0.02 dividend. The ex-dividend date was Monday, February 23rd. This represents a $0.08 dividend on an annualized basis and a dividend yield of 1.3%. Organon & Co.’s payout ratio is 11.27%.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.